We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
Read MoreHide Full Article
Ecolab Inc. (ECL - Free Report) recently announced that it will acquire Bioquell PLC to enhance offerings for life sciences and healthcare environments. The transaction is expected to close by the first quarter of 2019.
Per the terms of the deal, Bioquell shareholders will receive 590 pence per share after the acquisition. Ecolab will leverage on Bioquell’s innovative bio-decontamination and isolator platforms for residue-free surface decontamination. Notably, Andover, U.K.-based Bioquell’s sales amounted to $37 million in 2017.
About Ecolab’s Healthcare & Life Sciences Unit
Ecolab serves the markets of hospitals and surgery centers, long-term care, OEM healthcare manufacturing, and pharmaceutical services.
Additionally, the company’s new Health Department Intelligence (“HDI”) platform helps foodservice operators to properly understand their health inspection results, improve health inspection performance, and manage food safety risks across multiple sites in a better way.
Recently, this Zacks Rank #4 (Sell) company launched a Life Sciences cleanroom program in North America, developed specially for pharmaceutical manufacturing. The program provides comprehensive cleaning and disinfection for both sterile and non-sterile applications.
Other Strategic Acquisitions & Collaborations
In a bid to gain market traction and boost profits, Ecolab continues to focus on investment in key growth businesses and bolt-on acquisitions as well as collaborations and agreements with other companies.
In October, Nalco Champion, an Ecolab company, collaborated with Accenture and Microsoft to launch a new unified, digital platform – Refined Knowledge – powered by ECOLAB3D.
In August, Nalco Champion and XOS entered into an exclusive distribution agreement to provide a chlorine monitoring solution for the global refining industry.
In January, Ecolab acquired Cascade Water Services Inc. — a privately-held company, based in New York. Cascade Water Services provides water treatment programs and services to the U.S. institutional market.
Impressive Stock Performance
Ecolab’s stock has outperformed its industry in a year’s time. The company has gained almost 16.9% against the industry’s 3.5% decline. The current level is also higher than the S&P 500 index’s 4.5% growth.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Veeva Systems (VEEV - Free Report) .
With a Zacks Rank #1, STAAR Surgical delivered an average four-quarter positive earnings surprise of 400%.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank of 1.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
Ecolab Inc. (ECL - Free Report) recently announced that it will acquire Bioquell PLC to enhance offerings for life sciences and healthcare environments. The transaction is expected to close by the first quarter of 2019.
Per the terms of the deal, Bioquell shareholders will receive 590 pence per share after the acquisition. Ecolab will leverage on Bioquell’s innovative bio-decontamination and isolator platforms for residue-free surface decontamination. Notably, Andover, U.K.-based Bioquell’s sales amounted to $37 million in 2017.
About Ecolab’s Healthcare & Life Sciences Unit
Ecolab serves the markets of hospitals and surgery centers, long-term care, OEM healthcare manufacturing, and pharmaceutical services.
Additionally, the company’s new Health Department Intelligence (“HDI”) platform helps foodservice operators to properly understand their health inspection results, improve health inspection performance, and manage food safety risks across multiple sites in a better way.
Recently, this Zacks Rank #4 (Sell) company launched a Life Sciences cleanroom program in North America, developed specially for pharmaceutical manufacturing. The program provides comprehensive cleaning and disinfection for both sterile and non-sterile applications.
Other Strategic Acquisitions & Collaborations
In a bid to gain market traction and boost profits, Ecolab continues to focus on investment in key growth businesses and bolt-on acquisitions as well as collaborations and agreements with other companies.
In October, Nalco Champion, an Ecolab company, collaborated with Accenture and Microsoft to launch a new unified, digital platform – Refined Knowledge – powered by ECOLAB3D.
In August, Nalco Champion and XOS entered into an exclusive distribution agreement to provide a chlorine monitoring solution for the global refining industry.
In January, Ecolab acquired Cascade Water Services Inc. — a privately-held company, based in New York. Cascade Water Services provides water treatment programs and services to the U.S. institutional market.
Impressive Stock Performance
Ecolab’s stock has outperformed its industry in a year’s time. The company has gained almost 16.9% against the industry’s 3.5% decline. The current level is also higher than the S&P 500 index’s 4.5% growth.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Veeva Systems (VEEV - Free Report) .
Quidel Corporation has a long-term expected earnings growth rate of 25% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
With a Zacks Rank #1, STAAR Surgical delivered an average four-quarter positive earnings surprise of 400%.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank of 1.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>